Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Adenomatous Polyposis Coli 2Precancerous Conditions 1Colorectal Neoplasms 1Colonic Polyps 1

Interventions

Selenium 4Epoetin Alfa 3Vitamin E 2Darbepoetin alfa 2Aminolevulinic Acid 2tirbanibulin 1human papillomavirus vaccine, L1 type 16, 18 1ferrous sulfate 1ferric gluconate 1alpha-Tocopherol 1Watchful Waiting 1Vaginal Smears 1Toremifene 1Sulindac 1Sucrose 1Soybean Proteins 1Rosuvastatin Calcium 1Radiotherapy, Intensity-Modulated 1Polymerase Chain Reaction 1Ondansetron 1Morphine 1Light Coagulation 1Imiquimod 1Hypericum extract LI 160 1Fenretinide 1Esomeprazole 1Eflornithine 1Early Intervention, Educational 1Dextromethorphan 1Deoxyribonuclease (Pyrimidine Dimer) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Precancerous Conditions × Sulindac × Clear all
NCT00118365 2015-01-22

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

National Cancer Institute (NCI)

Phase 3 Completed
375 enrolled 27 charts
Other neoplasm

Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡